LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

SectorGezondheidszorg

67.7 -0.29

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.38

Max

69.24

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	24.112 50.102
EPS	1.221
Winstmarge	39.832
Werknemers	423
EBITDA	-63M 218M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+17.23% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	501M 8.2B
Vorige openingsprijs	67.99
Vorige sluitingsprijs	67.7

Nieuwssentiment

By Acuity

34%

66%

82 / 344 Rangschikking in Healthcare

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 mei 2026, 22:47 UTC

Winsten

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mei 2026, 20:45 UTC

Winsten

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mei 2026, 23:39 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mei 2026, 23:31 UTC

Marktinformatie

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mei 2026, 23:17 UTC

Marktinformatie

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mei 2026, 23:02 UTC

Marktinformatie

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mei 2026, 22:37 UTC

Marktinformatie

Acquisities, Fusies, Overnames

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mei 2026, 21:12 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mei 2026, 21:00 UTC

Winsten

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mei 2026, 20:57 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:55 UTC

Winsten

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

28 mei 2026, 20:48 UTC

Populaire aandelen

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mei 2026, 20:34 UTC

Winsten

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mei 2026, 20:31 UTC

Winsten

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mei 2026, 20:28 UTC

Winsten

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mei 2026, 20:26 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Membership Fees $1.37B

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Net Sales $69.15B

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

17.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.48 USD 17.23%

Hoogste 96 USD

Laagste 66.41 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

82 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.